Ocular Therapeutix (NASDAQ: OCUL) reported Q4 EPS of ($0.24), $0.01 better than the analyst estimate of ($0.25). Revenue for the quarter came in at $14.1 million versus the consensus estimate of $13.42 million.

For earnings history and earnings-related data on Ocular Therapeutix (OCUL) click here.